Fiche récapitulative
The project will support the promoter, a biotech company, in advancing its clinical candidates and proprietary messenger ribonucleic acid (mRNA) platform targeting respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD).
The aim is to contribute to pandemic preparedness, as the mechanism of action of the mRNA platform is designed to enhance innate human immune responses at the respiratory mucosa.
The specific research, development and innovation (RDI) activities included in the project are expected to be performed in existing facilities without changing their already authorised scope. Therefore, the project activities would not require an Environmental Impact Assessment (EIA) under the Directive 2014/52/EU (amending the Directive 2011/52/EU). Full environmental details will be verified during appraisal.
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is generally not covered by EU directives on procurement. However, the EIB will require that all project contracts are procured in accordance with the applicable EU procurement legislation. The Bank's services will verify details during the project due diligence.